Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report

Akamatsu, 2013, Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405), Jpn. J. Clin. Oncol., 43, 664, 10.1093/jjco/hyt049 Kobayashi, 2018, Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer, OncoTargets Ther., 11, 3335, 10.2147/OTT.S161745 Sequist, 2011, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci. Transl. Med., 3, 10.1126/scitranslmed.3002003 Yu, 2013, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin. Canc. Res., 19, 2240, 10.1158/1078-0432.CCR-12-2246 Roca, 2017, Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: a systematic review and pooled analysis, Cancer Treat Rev., 59, 117, 10.1016/j.ctrv.2017.07.007 Araki, 2017, A case of transformation to small-cell lung cancer as an acquired resistance in EGFR-mutant lung adenocarcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor, Ann. Jpn. Respir. Soc., 6, 99 Watanabe, 2013, Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma, Lung Canc., 82, 370, 10.1016/j.lungcan.2013.06.003 Oser, 2015, Transformation from non-small-cell lung cancer to small-cell lung cancer : molecular drivers and cell of origins, Lancet Oncol., 16, 165, 10.1016/S1470-2045(14)71180-5 Niederst, 2015, RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer, Nat. Commun., 6, 6377, 10.1038/ncomms7377 Fujita, 2016, Concomitant T790M mutation and small-cell lung cancer transformation after acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor, Respirol. Case Rep., 5 Xu, 2017, A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity, Anti Canccer Drugs, 9, 1056, 10.1097/CAD.0000000000000540 Ali, 2016, Small cell lung cancer transformation and the T790M mutation: a case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma, Oncol. Lett., 12, 4009, 10.3892/ol.2016.5193 Kuiper, 2014, Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients, Lung Canc., 85, 19, 10.1016/j.lungcan.2014.03.016 Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N. Engl. J. Med., 366, 883, 10.1056/NEJMoa1113205 Sun, 2013, Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors, Lung Canc., 82, 294, 10.1016/j.lungcan.2013.08.023 Malapelle, 2017, Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer, Expert Rev. Mol. Diagn, 17, 209, 10.1080/14737159.2017.1288568 Weber, 2014, Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays, BMC Canc., 14, 294, 10.1186/1471-2407-14-294